TABLE 2.
Virological outcome of patients using First-line NAs in propensity matching cohort
| All subjects | GG | GA | p# | Odds ratio (95%CI) | |
|---|---|---|---|---|---|
| Primary nonresponse (%) | 11/136 (8.09) | 11/68 (16.18) | 0/68 (0) | < 0.001 | 0.84 (0.76, 0.93) |
| ETV (%) | 7/110 (6.36) | 7/55 (12.73) | 0/55 (0) | 0.013 | 0.87 (0.79, 0.97) |
| TDF (%) | 4/26 (15.38) | 4/13 (30.77) | 0/13 (0) | 0.096 | 0.69 (0.48, 1.00) |
| Partial virological response (%) | 40/136 (29.41) | 25/68 (36.76) | 15/68 (22.06) | 0.090 | 0.49 (0.23, 1.04) |
| ETV (%) | 30/110 (27.27) | 20/55 (36.36) | 10/55 (18.18) | 0.053 | 0.39 (0.16, 0.94) |
| TDF (%) | 10/26 (38.46) | 5/13 (38.46) | 5/13 (38.46) | 1.000 | 1.00 (0.21, 4.86) |
| Virological breakthrough (%) | 13/111 (11.71) | 7/60 (11.67) | 6/51 (11.76) | 1.000 | 1.01 (0.32, 3.22) |
| ETV (%) | 10/92 (10.87) | 6/50 (12) | 4/42 (9.52) | 0.750 | 0.77 (0.20, 2.94) |
| TDF (%) | 3/19 (15.79) | 1/10 (10) | 2/9 (22.22) | 0.582 | 2.57 (0.19, 34.47) |
| Reactivation of hepatitis B (%) | 7/111 (6.31) | 4/60 (6.67) | 3/51 (5.88) | 1.000 | 0.88 (0.19, 4.11) |
| ETV (%) | 6/92 (6.52) | 4/50 (8) | 2/42 (4.76) | 0.684 | 0.58 (0.10, 3.31) |
| TDF (%) | 1/19 (5.26) | 0/10 (0) | 1/9 (11.11) | 0.474 | 1.13 (0.89, 1.42) |
#p - value between GG and GA group. Significant p-value in bold (threshold p < 0.05).